Overview

Pathogenicity: Globular Glial Tauopathy : Pathogenic
Clinical Phenotype: Globular Glial Tauopathy
Position: (GRCh38/hg38):Chr17:46014278 G>C
Position: (GRCh37/hg19):Chr17:44091644 G>C
dbSNP ID: NA
Coding/Non-Coding: Coding
DNA Change: Substitution
Expected RNA Consequence: Substitution
Expected Protein Consequence: Missense
Codon Change: AAG to AAC
Reference Isoform: Tau Isoform Tau-F (441 aa)
Genomic Region: Exon 11

Findings

This mutation was detected in a woman with a constellation of symptoms suggestive of frontotemporal dementia, progressive supranuclear palsy, and motor neuron disease (Tacik et al., 2015). Her disease was categorized as globular glial tauopathy (GGT), a rare four-repeat tauopathy characterized by tau inclusions in astrocytes and oligodendrocytes (Ahmed et al., 2011).

Clinically her disease started at the age of 64 with increasing speech difficulties, especially in producing the correct sounds, consistent with primary progressive apraxia of speech. Over a five-year disease duration, she developed cognitive impairment and parkinsonism symptoms, including postural instability, bradykinesia, and limb apraxia, as well as symptoms suggestive of PSP, including vertical gaze palsy. She also had signs of lower motor neuron disease, including muscle fasiculations. Her disease was classified as subtype III of globular glial tauopathy, which is associated with features of both FTD and motor neuron disease.

The mutation carrier had a family history of dementia. Her mother and maternal aunt were clinically diagnosed with Alzheimer’s dementia. They died at the ages of 63 and 70 years, respectively. It is not known if they carried the K317N mutation.

Neuropathology

Autopsy showed lobar atrophy, especially in the inferior frontal gyrus, but also in premotor and motor cortices (Tacik et al., 2015). White-matter pathology was observed, including vacuoles, gliosis, and loss of myelinated fibers. Extensive tau pathology was present, with tau-positive inclusions in neurons, astrocytes, and oligodendrocytes. The neuronal inclusions resembled pretangles with a limited number of neurofibrillary tangles, predominantly in the anteromedial temporal lobe (Braak stage III). The lesions in astrocytes were described as Gallyas silver–positive granular or globular inclusions. In the white matter there were many globular oligodendroglial inclusions and coiled bodies. The distribution of tau pathology was consistent with a diagnosis of GGT subtype III.

Neither amyloid plaques nor Lewy bodies were observed. The substantia nigra was depigmented with neuronal tau inclusions. There was mild pathology in the corticospinal tract.

Biological Effect

Recombinant tau with the K317N mutation exhibited impaired tubulin polymerization (Tacik et al., 2015). In addition, the mutation affected tau aggregation in an isoform-specific manner. The mutation accelerated tau filament assembly in 4R tau while decreasing tau aggregation, misfolding, and filament assembly in 3R tau. Interestingly, an in vitro study found that the acetylation of lysines, including K317, accelerated aggregation in 3R tau (Oct 2023 news, Chabkraborty et al., 2023). 

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

1. Acetylation Accelerates Aggregation of 3R, but Not 4R, Tau 6 Oct 2023

Paper Citations

1. Tacik P, DeTure M, Lin WL, Sanchez Contreras M, Wojtas A, Hinkle KM, Fujioka S, Baker MC, Walton RL, Carlomagno Y, Brown PH, Strongosky AJ, Kouri N, Murray ME, Petrucelli L, Josephs KA, Rademakers R, Ross OA, Wszolek ZK, Dickson DW. A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathol. 2015 Aug;130(2):199-214. Epub 2015 Apr 22 PubMed.
2. Ahmed Z, Doherty KM, Silveira-Moriyama L, Bandopadhyay R, Lashley T, Mamais A, Hondhamuni G, Wray S, Newcombe J, O'Sullivan SS, Wroe S, de Silva R, Holton JL, Lees AJ, Revesz T. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol. 2011 Oct;122(4):415-28. PubMed.
3. Chakraborty P, Rivière G, Hebestreit A, de Opakua AI, Vorberg IM, Andreas LB, Zweckstetter M. Acetylation discriminates disease-specific tau deposition. Nat Commun. 2023 Sep 22;14(1):5919. PubMed.

Further Reading

No Available Further Reading